Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Unite-CNM: DYN101 in Centronuclear Myopathies
NCT04033159Phase 2Terminated
- Sponsor
- Dynacure
- Start
- Jan 2020
- Primary completion
- Jun 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 6
01
Overview
A Phase 2 trial of DYN101 in centronuclear myopathy (CNM), sponsored by Dynacure. Started Jan 2020; status: terminated.
02
Drugs
DYN101
03
Conditions
centronuclear myopathy (CNM)
Beyond the preview
Go deeper on NCT04033159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04033159.